Arlington Trust Co LLC Buys 1,138 Shares of Edwards Lifesciences Corporation $EW

Arlington Trust Co LLC raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.3% during the 2nd quarter, Holdings Channel reports. The fund owned 12,230 shares of the medical research company’s stock after purchasing an additional 1,138 shares during the period. Arlington Trust Co LLC’s holdings in Edwards Lifesciences were worth $957,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Valeo Financial Advisors LLC boosted its position in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after purchasing an additional 142 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of Edwards Lifesciences by 9.3% in the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock worth $123,000 after purchasing an additional 145 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares in the last quarter. Kera Capital Partners Inc. boosted its position in shares of Edwards Lifesciences by 5.0% in the 1st quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company’s stock worth $224,000 after purchasing an additional 148 shares in the last quarter. Finally, Leo Wealth LLC boosted its position in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after purchasing an additional 150 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on EW shares. Mizuho raised their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 25th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $86.26.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 0.7%

EW stock opened at $77.50 on Monday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The stock has a market cap of $45.50 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.74 and a beta of 1.07. The business’s 50-day moving average is $78.92 and its 200 day moving average is $75.45.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the firm posted $0.70 EPS. Edwards Lifesciences’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.